| The Emerging Evidence of the Parkinson Pandemic |
64 |
| Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease |
39 |
| Brain-First versus Gut-First Parkinson's Disease: A Hypothesis |
24 |
| Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease: A Systematic Review |
22 |
| Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents |
22 |
| Modeling Parkinson's Disease in C. elegans |
20 |
| Parkinson's Disease in Women and Men: What's the Difference? |
19 |
| Mobilizing Parkinson's Disease: The Future of Exercise |
18 |
| Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson's Disease |
16 |
| Parkinson's Disease and Melanoma: Co-Occurrence and Mechanisms |
15 |
| High Prevalence of Undiagnosed Insulin Resistance in Non-Diabetic Subjects with Parkinson's Disease |
14 |
| Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells |
14 |
| The Gut and Parkinson's Disease: Hype or Hope? |
14 |
| Gene Therapy for Parkinson's Disease, An Update |
13 |
| The Amphetamine Induced Rotation Test: A Re-Assessment of Its Use as a Tool to Monitor Motor Impairment and Functional Recovery in Rodent Models of Parkinson's Disease |
13 |
| A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein |
13 |
| Semaglutide is Neuroprotective and Reduces alpha-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease |
13 |
| The Voice of the Parkinson Customer |
13 |
| Management of Parkinson's Disease 20 Years from Now: Towards Digital Health Pathways |
12 |
| Patient Views on Telemedicine for Parkinson Disease |
11 |
| Effects of Dance on Gait, Cognition, and Dual-Tasking in Parkinson's Disease: A Systematic Review and Meta-Analysis |
10 |
| Towards Personalized Rehabilitation for Gait Impairments in Parkinson's Disease |
10 |
| The Future of Brain Imaging in Parkinson's Disease |
9 |
| MDSGene: Closing Data Gaps in Genotype-Phenotype Correlations of Monogenic Parkinson's Disease |
9 |
| Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease |
9 |
| The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease |
9 |
| What is Functional Mobility Applied to Parkinson's Disease? |
9 |
| The Effect of Different Exercise Modes on Domain-Specific Cognitive Function in Patients Suffering from Parkinson's Disease: A Systematic Review of Randomized Controlled Trials |
8 |
| Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson's Disease |
8 |
| The Search for Environmental Causes of Parkinson's Disease: Moving Forward |
8 |
| Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence |
8 |
| Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease |
8 |
| Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies |
7 |
| Sleep Disturbance as Potential Risk and Progression Factor for Parkinson's Disease |
7 |
| Evolvability and Neurodegenerative Disease: Antagonistic Pleiotropy Phenomena Derived from Amyloid Aggregates |
7 |
| The European Physiotherapy Guideline for Parkinson's Disease: Implications for Neurologists |
7 |
| Progression of Cognitive Decline in Parkinson's Disease |
7 |
| Effect of Low versus High Frequency Subthalamic Deep Brain Stimulation on Speech Intelligibility and Verbal Fluency in Parkinson's Disease: A Double-Blind Study |
6 |
| Qualitative Evaluation of the Personal KinetiGraph (TM) Movement Recording System in a Parkinson's Clinic |
6 |
| Safety Profile of Opicapone in the Management of Parkinson's Disease |
6 |
| Cognitive Rehabilitation in Parkinson's Disease: A Systematic Review |
6 |
| What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis |
6 |
| The Effect of Short Pulse Width Settings on the Therapeutic Window in Subthalamic Nucleus Deep Brain Stimulation for Parkinson's disease |
6 |
| How Mobile Health Technology and Electronic Health Records Will Change Care of Patients with Parkinson's Disease |
6 |
| Therapies to Slow, Stop, or Reverse Parkinson's Disease |
6 |
| Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for alpha-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4) |
5 |
| Parkinson Matters |
5 |
| Cognitive Interventions in Parkinson's Disease: Where We Want to Go within 20 Years |
5 |
| How I do it: The Neuro-Ophthalmological Assessment in Parkinson's Disease |
5 |
| Progressive Changes in the Retinal Structure of Patients with Parkinson's Disease |
5 |
